Eddy Yang

25PUBLICATIONS
160CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Cancer geneticsPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|May 15, 2024
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With <i>ERBB2/3</i> Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Timothy L Cannon, Michael Rothe, Pam K Mangat

|Aug 26, 2023
Combination Therapy with Trastuzumab and Niraparib: Quantifying Early Proliferative Alterations in HER2+ Breast Cancer Models.

Ameer Mansur, Patrick N Song, Yun Lu

|Jul 27, 2023
Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.

Benjamin J Bulen, Nickolay A Khazanov, Daniel H Hovelson

|Feb 08, 2023
Olaparib in Patients With Metastatic Prostate Cancer With <i>BRCA1</i>/<i>2</i> Mutation: Results From the TAPUR Study.

Eddy S Yang, Susan Halabi, Michael Rothe

|Feb 03, 2023
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer.

Christos Vaklavas, Erica M Stringer-Reasor, Ahmed M Elkhanany

|Jan 11, 2023
An Assessment of the Feasibility and Utility of an ACCC-ASCO Implicit Bias Training Program to Enhance Racial and Ethnic Diversity in Cancer Clinical Trials.

Nadine J Barrett, Leigh Boehmer, Janelle Schrag

Pageof 5

Frequent Collaborators

3 joint publications

Elizabeth Garrett-Mayer

3 joint publications

Anna G Sorace

2 joint publications

Andrew C Burns

2 joint publications

Al Benson